ANGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AngioDynamics's average Accounts Payable for the three months ended in Feb. 2024 was $36.4 Mil. AngioDynamics's Cost of Goods Sold for the three months ended in Feb. 2024 was $39.3 Mil. Hence, AngioDynamics's Days Payable for the three months ended in Feb. 2024 was 84.47.
The historical rank and industry rank for AngioDynamics's Days Payable or its related term are showing as below:
During the past 13 years, AngioDynamics's highest Days Payable was 78.51. The lowest was 39.29. And the median was 57.16.
AngioDynamics's Days Payable increased from Feb. 2023 (79.76) to Feb. 2024 (84.47). It may suggest that AngioDynamics delayed paying its suppliers.
The historical data trend for AngioDynamics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AngioDynamics Annual Data | |||||||||||||||||||||
Trend | May14 | May15 | May16 | May17 | May18 | May19 | May20 | May21 | May22 | May23 | |||||||||||
Days Payable | Get a 7-Day Free Trial | 61.46 | 67.18 | 52.66 | 57.82 | 75.98 |
AngioDynamics Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Days Payable | Get a 7-Day Free Trial | 79.76 | 77.59 | 77.09 | 73.42 | 84.47 |
For the Medical Instruments & Supplies subindustry, AngioDynamics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Days Payable distribution charts can be found below:
* The bar in red indicates where AngioDynamics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AngioDynamics's Days Payable for the fiscal year that ended in May. 2023 is calculated as
Days Payable (A: May. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: May. 2022 ) | + | Accounts Payable (A: May. 2023 )) | / | count ) | / | Cost of Goods Sold (A: May. 2023 ) | * | Days in Period |
= | ( (28.047 | + | 40.445) | / | 2 ) | / | 164.506 | * | 365 |
= | 34.246 | / | 164.506 | * | 365 | ||||
= | 75.98 |
AngioDynamics's Days Payable for the quarter that ended in Feb. 2024 is calculated as:
Days Payable (Q: Feb. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Nov. 2023 ) | + | Accounts Payable (Q: Feb. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Feb. 2024 ) | * | Days in Period |
= | ( (37.65 | + | 35.152) | / | 2 ) | / | 39.321 | * | 365 / 4 |
= | 36.401 | / | 39.321 | * | 365 / 4 | ||||
= | 84.47 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of AngioDynamics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Lorinda Burgess | director | 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093 |
Karen A Licitra | director | C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050 |
Michael E Tarnoff | director | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Scott Centea | officer: SVP/GM, VIT | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Dave Helsel | officer: SVP Global Operations and R&D | 400 WOOD ROAD, BRAINTREE MA 02184 |
Laura Piccinini | officer: SVP International | C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Stephen A Trowbridge | officer: SVP and General Counsel | 14 PLAZA DRIVE, LATHAM NY 120110 |
James C Clemmer | director, officer: President and CEO | COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Wesley Johnson | director | |
Chad Thomas Campbell | officer: SVP/GM, Vascular Access | 140 POKANOKET PATH, WRENTHAM MA 02093 |
Warren Jr Nighan | officer: SVP Quality and Regulatory | ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Richard C Rosenzweig | officer: SVP and General Counsel | C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Kevin J Gould | director | 247 WASHINGTON STREET, DUXBURY MA 02332 |
Brent J. Boucher | officer: SVP and GM of Oncology | 14 PLAZA DRIVE, LATHAM NY 12110 |
Michael Greiner | officer: EVP and CFO | C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire • 10-04-2023
By Business Wire • 07-24-2023
By Business Wire • 01-23-2024
By Business Wire Business Wire • 12-15-2022
By Business Wire Business Wire • 02-08-2022
By Business Wire • 09-12-2023
By Business Wire • 12-07-2023
By Business Wire Business Wire • 04-04-2022
By Business Wire Business Wire • 12-20-2022
By Business Wire Business Wire • 12-15-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.